Springworks Therapeutics, Inc. SEC Filings

Welcome to our dedicated page for Springworks Therapeutics SEC filings (Ticker: SWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

This page provides access to historical U.S. Securities and Exchange Commission (SEC) filings associated with SpringWorks Therapeutics, Inc., which previously traded on Nasdaq under the ticker SWTX. These documents trace the company’s evolution from a standalone commercial-stage biopharmaceutical issuer to its acquisition by Merck KGaA, Darmstadt, Germany and subsequent deregistration as a public company.

For investors analyzing SWTX, key filings include current reports on Form 8-K describing material events such as the April 27, 2025 Agreement and Plan of Merger and the July 1, 2025 completion of the merger in which a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany merged with and into SpringWorks. The July 1, 2025 Form 8-K explains that SpringWorks became a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany, that each share of common stock was converted into the right to receive cash consideration, and that a change in control occurred.

Listing and registration changes are documented in a Form 25 filed by The Nasdaq Stock Market LLC on July 1, 2025, which notifies the SEC of the removal of SpringWorks common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. A subsequent Form 15 filed by SpringWorks on July 11, 2025 certifies the termination of registration of its common stock under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d), noting one holder of record as of the certification date.

Earlier periodic and transactional filings, such as annual and quarterly reports and proxy materials, provide additional detail on SpringWorks’ business, including the development and commercialization of OGSIVEO (nirogacestat) for desmoid tumors and GOMEKLI (mirdametinib) for NF1-PN, as well as its pipeline of targeted therapy product candidates. Together, these filings offer a regulatory history of SWTX, from its time as a listed issuer through its acquisition and delisting.

On Stock Titan, users can view these filings in sequence and use AI-powered tools to summarize lengthy documents, highlight key terms such as merger consideration, delisting notices, or risk factor language, and quickly locate references to specific products, clinical programs or corporate actions in the SpringWorks Therapeutics filing record.